Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF BUSINESS OFFICER | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,411 |
Ending reported balance
After 2026-06-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-10 · Sale · Disposed 3,711 · Balance 73,411 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. Row 2 · 2026-06-10 · Exercise / conversion · Acquired 17,566 · Balance 90,977 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. Row 3 · 2026-06-10 · Sale · Disposed 17,566 · Balance 73,411 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.01 · Expires 2028-01-02 | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-10 · Sale · Disposed 17,566 · Balance 0 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. F2: Currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026.
F2: Currently exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleStock Option (Right to Buy) · Derivative | 17,566 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001323212-26-000010 · form4-06122026_050610.xml · derivative · entry 4 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,566 shares Expires 2028-01-02 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 17,566 | $75.00 | $1,317,450.00 |
DisclosureSEC source: 0001323212-26-000010 · form4-06122026_050610.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,411 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 17,566 | $18.01 | $316,363.66 |
DisclosureSEC source: 0001323212-26-000010 · form4-06122026_050610.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,711 | $75.00 | $278,325.00 |
DisclosureSEC source: 0001323212-26-000010 · form4-06122026_050610.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,411 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,019 | $69.36 | $209,397.84 |
DisclosureSEC source: 0001323212-26-000008 · form4-02202026_050207.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,122 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a February 15, 2024 grant of 22,000 RSUs and the vesting of 1,150 RSUs from a February 15, 2024 grant of 2,300 RSUs. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,024 | $78.70 | $80,588.80 |
DisclosureSEC source: 0001323212-26-000006 · form4-01122026_050109.xml · nonDerivative · entry 5 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,141 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.16 to $79.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,722 | $77.41 | $133,300.02 |
DisclosureSEC source: 0001323212-26-000006 · form4-01122026_050109.xml · nonDerivative · entry 4 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,165 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,454 | $76.45 | $111,158.30 |
DisclosureSEC source: 0001323212-26-000006 · form4-01122026_050109.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,887 F4 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 587 | $76.98 | $45,187.26 |
DisclosureSEC source: 0001323212-26-000006 · form4-01122026_050109.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,341 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.91 to $77.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,561 | $76.42 | $195,711.62 |
DisclosureSEC source: 0001323212-26-000006 · form4-01122026_050109.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,928 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.89 to $76.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,352 | $77.48 | $104,752.96 |
DisclosureSEC source: 0001323212-26-000004 · form4-01082026_050119.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,489 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,789 | $76.95 | $137,663.55 |
DisclosureSEC source: 0001323212-26-000004 · form4-01082026_050119.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,841 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a January 3, 2025 grant of 22,000 RSUs. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001323212-26-000002 · form4-01062026_050121.xml · derivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-01-01 F3 · derivative.exercise_date: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001323212-26-000002 · form4-01062026_050121.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,630 F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. F2 · balance_after: Includes 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,805 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · derivative · entry 16 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,805 shares Expires 2031-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F12 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 565 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · derivative · entry 15 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,566 Underlying: Common Stock · 565 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F12 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 138 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · derivative · entry 14 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,805 Underlying: Common Stock · 138 shares Expires 2031-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F12 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,220 | $78.33 | $252,222.60 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 13 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F11 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.13 to $78.56 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,548 | $77.55 | $817,997.40 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 12 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,593 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $78.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,537 | $76.33 | $346,309.21 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 11 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,141 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.05 to $76.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,500 | $75.77 | $113,655.00 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 10 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,678 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.05 to $76.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 19,805 | $66.49 | $1,316,834.45 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 9 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 59 | $78.43 | $4,627.37 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 8 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.34 to $78.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 313 | $77.73 | $24,329.49 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 7 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,432 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.25 to $78.22 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 193 | $75.45 | $14,561.85 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 6 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,745 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.04 to $75.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 565 | $18.01 | $10,175.65 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 5 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 59 | $78.01 | $4,602.59 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 4 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.65 to $78.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 42 | $77.26 | $3,244.92 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,432 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.60 to $77.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 37 | $75.66 | $2,799.42 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,474 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.20 to $76.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 138 | $66.49 | $9,175.62 |
DisclosureSEC source: 0001323212-25-000006 · form4-12232025_051201.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 251 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · derivative · entry 18 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,131 Underlying: Common Stock · 251 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,951 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · derivative · entry 17 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,943 Underlying: Common Stock · 2,951 shares Expires 2031-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,831 | $75.07 | $212,523.17 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 14 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.00 to $75.20 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,831 | $66.49 | $188,233.19 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 13 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 251 | $75.00 | $18,825.00 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 12 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 251 | $18.01 | $4,520.51 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 11 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 120 | $75.02 | $9,002.40 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 10 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.00 to $75.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 120 | $66.49 | $7,978.80 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 9 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,684 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · derivative · entry 16 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,382 Underlying: Common Stock · 3,684 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,606 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · derivative · entry 15 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,894 Underlying: Common Stock · 36,606 shares Expires 2031-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $76.00 | $7,600.00 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 8 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 35,261 | $75.44 | $2,660,089.84 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 7 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,473 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.00 to $75.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 35,361 | $66.49 | $2,351,152.89 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 6 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $76.00 | $7,600.00 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 5 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,373 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,584 | $75.31 | $269,911.04 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 4 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,473 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.00 to $75.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,684 | $18.01 | $66,348.84 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,245 | $75.28 | $93,723.60 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.00 to $75.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,245 | $66.49 | $82,780.05 |
DisclosureSEC source: 0001323212-25-000003 · form4-12192025_051201.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 21 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F10 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,238 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 20 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,238 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F10 · derivative.exercise_date: Currently exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.